Advancements and Applications of Antibody Drug Conjugates in HER2-Negative Breast Cancer

Patients with triple-negative and HR-positive/HER2-negative breast cancer have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients and results in treatment disparities. Antibody-drug conjugates (ADCs) are novel agents which may improve patient outcomes. However, clinicians cannot implement them into practice appropriately or may be hesitant to use them altogether.

In this Grand Rounds activity, a breast cancer expert will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

Learn more:  https://www.ceconcepts.com/activity/advancements-and-applications-of-antibody-drug-conjugates-in-her2-negative-breast-cancer/